Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04387201 · ClinicalTrials.gov registry record · Phase 4
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT04387201 is a Phase 4 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 23 participants.
The verdict
NCT04387201, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
This project investigates the anti-obesity mechanisms of glucagon-like peptide-1 (GLP-1) analogs, which are used in the treatment of human obesity and diabetes mellitus. The investigators will test if GLP-1 induces secretion of interleukin-6 (IL-6), a cytokine that may collaborate with GLP-1 analogs to induce the formation of brown fat, which has anti-diabetic properties. The results will guide future obesity and diabetes mellitus therapies.
Interventions
- DRUG Dulaglutide
- DRUG Cyanocobalamin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-05-15 |
| Est. Completion | 2023-10-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04387201
The ClinicalTrials.gov registry entry for NCT04387201 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dulaglutide is the first listed.
NCT04387201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04387201 about?
NCT04387201 is a clinical study titled "GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response". This project investigates the anti-obesity mechanisms of glucagon-like peptide-1 (GLP-1) analogs, which are used in the treatment of human obesity and diabetes mellitus. The investigators will test if GLP-1 induces secretion of interleukin-6 (IL-6), a cytokine that may collaborate with GLP-1 analogs...
What is the current status of trial NCT04387201?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2020-05-15. Estimated completion is 2023-10-06.
What interventions are being tested in trial NCT04387201?
The interventions under investigation include: Dulaglutide (DRUG), Cyanocobalamin (DRUG).
Who is sponsoring clinical trial NCT04387201?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.